Point72 Asset Management
ABOS icon

Point72 Asset Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Point72 Asset Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-67,375
Closed -$159K – 3926
2026
Q1 		$159K Buy
67,375
+31,010
+85% +$79.1K ﹤0.01% 3563
2025
Q4 		$76.7K Buy
+36,365
New +$72.1K ﹤0.01% 3759
2023
Q2 		– Sell
-3,954
Closed -$16.1K – 2109
2023
Q1 		$16.1K Buy
+3,954
New +$20.6K ﹤0.01% 1996
2022
Q4 		– Sell
-40,936
Closed -$411K – 1476
2022
Q3 		$411K Buy
+40,936
New +$235K ﹤0.01% 1196
2022
Q2 		– Sell
-55,054
Closed -$215K – 1380
2022
Q1 		$215K Buy
+55,054
New +$300K ﹤0.01% 1060

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Point72 Asset Management's ABOS Position: Q2 2026 in Review

Point72 Asset Management sold out of Acumen Pharmaceuticals (ABOS) in Q2 2026, closing a stake of 67,375 shares — an estimated $159K sold.

Point72 Asset Management first reported a position in ABOS in Q1 2022 and held it in 5 quarters. The position peaked at $411K in Q3 2022. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Point72 Asset Management reported no remaining Acumen Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Point72 Asset Management sold 67,375 Acumen Pharmaceuticals shares in Q2 2026, an estimated $159K.
  • Point72 Asset Management first reported a position in Acumen Pharmaceuticals in Q1 2022 and held it in 5 quarters.
  • Point72 Asset Management's Acumen Pharmaceuticals position peaked at $411K in Q3 2022.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.